Market Overview

UPDATE: Credit Suisse Upgrades WuXi PharmaTech to Outperform on Growth Drivers

Share:
Related WX
Benzinga's Weekend M&A Chatter
Benzinga's Volume Movers
M&A Daily: GE & The Beer Fridge (Seeking Alpha)

Credit Suisse raised its rating on WuXi PharmaTech (NYSE: WX) from Neutral to Outperform and increased the price target from $14 to $18.

Credit Suisse noted, "We believe the market under- appreciated WuXi's potential upside from its core growth drivers: (i) Vertically integrated service offerings could benefit more than expected; (ii) Manufacturing business will be scaled-up driven by robust pipelines (four customer drugs move into commercial stage); (iii) Biologics business is on the rise in China, first mover to capture most value (pioneer in setting JV with MNCs such as the AstraZeneca-MedImmune deal)."

WuXi PharmaTech closed at $13.94 on Wednesday.

Latest Ratings for WX

DateFirmActionFromTo
Mar 2015Goldman SachsDowngradesConviction BuyNeutral
Nov 2014JefferiesDowngradesBuyHold
Oct 2013JefferiesMaintainsBuy

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (WX)

Get Benzinga's Newsletters